Suppression of AP-1 constitutive activity interferes with polyomavirus MT antigen transformation ability

Journal of Cellular Biochemistry

Volumn 90, Issue 2, 2003, Pages 253-266

  Winnischofer, Sheila Maria Brochado ^a   De Oliveira, Maria Leonor Sarno ^a,b   Sogayar, Mari Cleide ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

AP 1 activation; Cell transformation; Middle T antigen; Polyomavirus

Indexed keywords

AGAROSE; MT ANTIGEN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; MITOGENESIS; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VIRUS TRANSFORMATION;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; BALB 3T3 CELLS; CELL DIVISION; CELL TRANSFORMATION, VIRAL; GENE EXPRESSION REGULATION, VIRAL; GENES, DOMINANT; MICE; PHOSPHOTRANSFERASES; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TUMOR VIRUS INFECTIONS;

POLYOMAVIRUS;

EID: 0141864342     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10628     Document Type: Article

References (64)

1. Albanese C, D'Amico M, Reutens AT, Fu M, Watanabe G, Lee RJ, Kitsis RN, Henglein B, Avantaggiati M, Somasundaram K, Thimmapaya B, Pestell RG. 1999. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 274:34186-34195.
2. Angel P, Karin M. 1991. The role of Jun, Fos, and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1072:129-157.
3. Armelin MCS, Oliveira MLS. 1996. Polyomavirus-induced malignant transformation: Comparative analysis of wild type and mutant middle T-overexpressing cell lines. Braz J Med Biol Res 29:1133-1140.
4. Binétruy B, Smeal T, Karin M. 1991. Ha-Ras augments cJun activity and stimulates phosphorylation of its activation domain. Nature 351:122-127.
5. Blaikie PA, Fournier E, Dilworth SM, Birnbaum D, Borg JP, Margolis B. 1997. The role of the Shc phosphotyrosine interaction/phosphotyrosine binding domain and tyrosine phosphorylation sites in polyoma middle T antigen-mediated cell transformation. J Biol Chem 272:20671-20677.
6. Blochlinger K, Diggelmann H. 1984. Hygromycin B phosphotransferase as a selectable marker for DNA transfer experiments with higher eucaryotic cells. Mol Cell Biol 4:2929-2931.
7. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ. 1993. Suppression of oncogene induced transformation by a deletion mutant c-Jun. Oncogene 8:877-886.
8. Brown PH, Chen TK, Birrer MJ. 1994. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 9:791-799.
9. Campbell KS, Ogris E, Burke B, Su W, Auger KR, Druker BJ, Schaffhausen BS, Roberts TM, Pallas DC. 1994. Polyoma middle tumor antigen interacts with Shc protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. Proc Natl Acad Sci USA 91:6344-6348.
10. Campbell KS, Auger KR, Hemmings BA, Roberts TM, Pallas DC. 1995. Identification of regions in polyomavirus middle T and small T antigens important for association with protein phosphatase 2A. J Virol 69:3721-3728.
11. Carmichael GG, Schaffhausen BS, Mandel G, Liang TJ. 1984. Transformation by polyoma virus is drastically reduced by substitution of phenylalanine for tyrosine at residue 315 of middle-sized tumor antigen. Proc Natl Acad Sci USA 81:679-683.
12. Cherington V, Morgan B, Spiegelman BM, Roberts TM. 1986. Recombinant retroviruses that transduce individual polyoma tumor antigens: Effects on growth and differentiation. Proc Natl Acad Sci USA 83:4307-4311.
13. Choi I, Gudas LJ, Katzenellenbogen BS. 2000. Regulation of keratin 19 gene expression by estrogen in human breast cancer cells and identification of the estrogen responsive gene region. Mol Cell Endocrinol 164:225-237.
14. Courtneidge SA, Smith AE. 1983. Polyomavirus transforming protein associates with the product of the c-src cellular gene. Nature 303:435-439.
15. Culleré X, Rose P, Thathamangalam U, Chatterjee A, Mullane KP, Pallas DC, Benjamin TL, Roberts TM, Schaffhausen BS. 1998. Serine 257 phosphorylation regulates association of polyomavirus middle T antigen with 14-3-3 proteins. J Virol 72:558-563.
16. Del Valle L, Gordon J, Assimakopoulou M, Enam S, Geddes JF, Varakis JN, Katsetos CD, Croul S, Khalili K. 2001a. Detection of JC virus DNA sequences and expression of the viral regulatory protein T-antigen in tumors of the central nervous system. Cancer Res 61:4287-4293.
17. Del Valle L, Baehring J, Lorenzana C, Giordano A, Khalili K, Croul S. 2001b. Expression of a human polyomavirus oncoprotein and tumor suppressor proteins in medulloblastomas. Mol Pathol 54:331-337.
18. Dilworth SM. 2002. Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat Rev Cancer 2:951-956.
19. Dilworth SM, Brewster CEP, Jones MD, Lanfrancone L, Pelicci G, Pelicci PG. 1994. Transformation by polyomavirus middle T antigen involves the binding and tyrosine phosphorylation of Shc. Nature 367:87-90.
20. Doherty J, Freund R. 1997. Polyomavirus large T antigen overcomes p53 dependent growth arrest. Oncogene 14:1923-1931.
21. Druker BJ, Roberts TM. 1991. Generation of a large library of point mutations in polyoma middle T antigen. Nucleic Acids Res 19:6855-6861.
22. Druker BJ, Ling LE, Cohen B, Roberts TM, Schaffhausen BS. 1990. A completely transformation-defective point mutant of polyomavirus middle T antigen which retains full and associated phosphatidylinositol kinase activity. J Virol 64:4454-4461.
23. Druker BJ, Sibert L, Roberts TM. 1992. Polyomavirus middle T-antigen NPTY mutants. J Virol 66:5770-5776.
24. Dunant NM, Senften M, Ballmer-Hofer K. 1996. Polyomavirus middle T antigen associates with the kinase domain of Src-related tyrosine kinases. J Virol 70:1323-1330.
25. Freund R, Bronson RT, Benjamin TL. 1992. Separation of immortalization from tumor induction with polyoma large T mutants that fail to bind the retinoblastoma gene product. Oncogene 7:1979-1987.
26. Glenn GM, Eckhart W. 1993. Mutation of a cysteine residue in polyomavirus middle T antigen abolishes interactions with protein phosphatase 2A, pp60c-src, and phosphatidylinositol-3 kinase, activation of c-fos expression, and cellular transformation. J Virol 67:1945-1952.
27. Horak ID, Kawakami T, Gregory F, Robbins KC, Bolen JB. 1989. Association of p60fyn with middle tumor antigen in murine polyomavirus-transformed rat cells. J Virol 63:2343-2347.
28. Ichaso N, Dilworth SM. 2001. Cell transformation by the middle-T-antigen of polyoma virus. Oncogene 20:7908-7916.
29. Kaplan DR, Whitman M, Schaffhausen B, Pallas DC, White M, Cantley L, Roberts TM. 1987. Common elements in growth factor stimulation and oncogenic transformation: 85 kDa phosphoprotein and phosphatidylinositol kinase activity. Cell 50:1021-1029.
30. Karin M. 1995. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270:16483-16486.
31. Kornbluth S, Sudol M, Hanafusa H. 1986. Association of the polyomavirus middle T antigen with c-Yes protein. Nature 325:171-173.
32. Krynska B, Del Valle L, Croul S, Gordon J, Katsetos CD, Carbone M, Giordano A, Khalili K. 1999. Detection of human neutropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas. Proc Natl Acad Sci USA 96:11519-11524.
33. Liang TJ, Carmichael GG, Benjamin TL. 1984. A polyoma mutant that encodes small T antigen but not middle T antigen demonstrates uncoupling of cell surface and cytoskeletal changes associated with cell transformation. Mol Cell Biol 4:2772-2783.
34. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. 2002. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 21:7680-7689.
35. Matsubara H, Moriguchi Y, Mori Y, Masaki H, Tsutsumi Y, Shibasaki Y, Uchiyama-Tanaka Y, Fujiyama S, Koyama Y, Nose-Fujiyama A, Iba S, Tateishi E, Iwasaka T. 2000. Transactivation of EGF receptor induced by angiotensin II regulates fibronectin and TGF-beta gene expression via transcriptional and post-transcriptional mechanisms. Mol Cell Biochem 212:187-201.
36. Minden A, Lin A, McMahon M, Lange-Carter C, Dérijard B, Davis RJ, Johnson GL, Karin M. 1994. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266:1719-1723.
37. Morgan WC, Kaplan DR, Pallas DC, Roberts TM. 1988. Recombinant retroviruses that transduce middle T antigen cDNAs derived from polyomavirus mutants: Separation of focus formation and soft agar growth in transformation assays and correlation with kinase activities in vitro. J Virol 62:3407-3414.
38. Mullane KP, Ratnofsky M, Culleré X, Schaffhausen B. 1998. Signaling from polyomavirus middle T and small T defines different roles for protein phosphatase 2A. Mol Cell Biol 18:7556-7564.
39. Oliveira MLS, Roberts TM, Druker BJ, Armelin MCS. 1998. Mapping of polyomavirus middle T domain that is responsible for AP-1 activation. Oncogene 16:2975-2982.
40. Oliveira MLS, Brochado SM, Sogayar MC. 1999. Mechanisms of cell transformation induced by polyomavirus. Braz J Med Biol Res 32:861-865.
41. Pallas DC, Cherington V, Morgan W, DeAnda J, Kaplan D, Schaffhausen B, Roberts TM. 1988. Cellular proteins that associate with the middle T and small T antigens of polyomavirus. J Virol 62:3934-3940.
42. Pallas DC, Fu H, Haehnel LC, Weller W, Collier RJ, Roberts TM. 1994. Association of polyomavirus middle tumor antigen with 14-3-3 proteins. Science 265:535-537.
43. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. 1991. Phosphorylation of c-jun mediated by MAP kinases. Nature 353:670-674.
44. Qian W, Wiman KG. 2000. Polyoma virus middle T and small T antigens cooperate to antagonize p53-induced cell cycle arrest and apoptosis. Cell Growth Differ 11:31-39.
45. Rameh LE, Armelin MCS. 1991. T antigens role in polyomavirus transformation: c-myc but not cFos or cJun expression is a target for middle T. Oncogene 6:1049-1056.
46. Rameh LE, Armelin MCS. 1992. Downregulation of JE and KC genes by glucocorticoids does not prevent the G0 → G1 transition in Balb/3T3 cells. Mol Cell Biol 12:4612-4621.
47. Rapp UR, Troppmair J, Beck T, Birrer MJ. 1994. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant. Oncogene 9:3493-3498.
48. Rassoulzadegan M, Cowie A, Glaichenhaus N, Kamen R, Cuzin F. 1982. The roles of individual polyoma virus early proteins in oncogenic transformation. Nature 300:713-718.
49. Schlegel R, Benjamin TL. 1978. Cellular alterations dependent upon the polyomavirus ht-t function: Separation of mitogenic from transforming capacities. Cell 14:587-599.
50. Schöntal A, Srinivas S, Eckhart W. 1992. Induction of c-jun protooncogene expression and transcription factor AP-1 activity by the polyoma virus middle-sized tumor antigen. Proc Natl Acad Sci USA 89:4972-4976.
51. Smits P, Bhalerao J, Merregaert J. 1999. Molecular cloning and characterization of the mouse Ecm1 gene and its 5′ regulatory sequences. Gene 226:253-261.
52. Solis-Herrugo JA, Rippe RA, Schrum LW, de La Torre P, Garcia I, Jeffrey JJ, Munoz-Yague T, Brenner DA. 1999. Interleukin-6 increases rat metalloproteinase-13 gene expression through stimulation of activator protein 1 transcription factor in cultured fibroblasts. J Biol Chem 274:30919-30926.
53. Srinivas S, Schönthal A, Eckhart W. 1994. Polyomavirus middle sized tumor antigen modulates cJun phosphorylation and transcriptional activity. Proc Natl Acad Sci USA 91:10064-10068.
54. Su W, Liu W, Schaffhausen BS, Roberts TM. 1995. Association of polyomavirus middle tumor antigen with phospholipase C-γ-1. J Biol Chem 2705:12331-12334.
55. Tamura K, Chen YE, Lopez-Ilasaca M, Daviet L, Tamura N, Ishigami T, Akishita M, Takasaki I, Tokita Y, Pratt RE, Horiuchi M, Dzau VJ, Umemura S. 2000. Molecular mechanism of fibronectin gene activation by cyclic stretch in vascular smooth muscle cells. J Biol Chem 275:34619-34627.
56. Testa JR, Carbone M, Hirvonen A, Khalili K, Krynska B, Linnainmaa K, Pooley FR, Rizzo P, Rusch V, Xiang GH. 1998. Simian virus 40 DNA sequences are present in human malignant mesotheliomas. Cancer Res 58:4505-4509.
57. Treisman R, Novak U, Favaloro J, Kamen R. 1981. Transformation of rat cells by an altered polyoma virus genome expressing only the middle-T protein. Nature 292:595-600.
58. Vial E, Perez S, Castellazzi M. 2000. Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors. Oncogene 19:5020-5029.
59. Wang H, Birkenbach M, Hart J. 2000. Expression of Jun family members in human colorectal adenocarcinoma. Carcinogenesis 21:1313-1317.
60. Watanabe G, Howe A, Lee RJ, Albanese C, Shu IW, Karnezis AN, Zon L, Kyriakis J, Rundell K, Pestell RG. 1996. Induction of cyclin D1 by Simian virus 40 small tumor antigen. Proc Natl Acad Sci USA 93:12861-12866.
61. Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD, Colburn NH. 1998. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 17:3493-3498.
62. Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM. 1985. Association of phosphatidylinositol kinase activity with polyoma middle T competent for transformation. Nature 315:239-242.
63. Wisdom R, Johnson RS, Moore C. 1999. cJun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 18:188-197.
64. Zoumpourlis V, Paraskevi P, Linardopoulos S, Gillespie D, Balmain A, Pintzas A. 2000. High levels of phosphorylated c-Jun, Fra-1, Fra-2, and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene 19:4011-4021.